NCT03035032View on ClinicalTrials.gov

A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

June 23, 2017

Primary Completion Date

November 19, 2019

Study Completion Date

November 19, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Leuprolide

Subcutaneous Injection

Trial Locations (19)

Unknown

Site HK01001, Hong Kong

Site HK01002, Hong Kong

Site ID02001, Jakarta

Site MY03002, Batu Caves

Site MY03001, Kuala Lumpur

Site PH04001, Makati City

Site PH04003, Manila

Site PH04002, San Juan City

Site SG05001, Singapore

Site SG05002, Singapore

Site SG05003, Singapore

Site TW06001, Taichung

Site TW06002, Taichung

Site TW06003, Taipei

Site TH07004, Hat Yai

Site TH07001, Muang

Site TH07003, Bangkok

Site VN08001, Ho Chi Minh City

Site VN08002, Ho Chi Minh City

All Listed Sponsors
lead

Astellas Pharma Singapore Pte. Ltd.

INDUSTRY

NCT03035032 - A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients | Biotech Hunter | Biotech Hunter